Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

ClinicalTrials.gov ID: NCT00315380

Public ClinicalTrials.gov record NCT00315380. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Study identification

NCT ID: NCT00315380
Recruitment status: Recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: University of Pennsylvania; Other
Enrollment: 700 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2006
Primary completion: Nov 30, 2028
Completion: Nov 30, 2028
Last update posted: Aug 27, 2026

2006 – 2028

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California San Diego	San Diego	California	92122	Completed
National Jewish Health	Denver	Colorado	80206	Completed
Brigham and Women's Hospital	Boston	Massachusetts	02215	Completed
Mayo Clinic	Rochester	Minnesota	55905	Completed
Cleveland Clinic Foundation	Cleveland	Ohio	44195	Completed
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Completed
University of Pittsburgh	Pittsburgh	Pennsylvania	15260	Completed
University of Utah	Salt Lake City	Utah	84112	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00315380, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 27, 2026 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00315380 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →